LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD ...

Acute chest syndrome (ACS), a life-threatening complication of sickle cell disease (SCD), may be driven by overactivation of ...

Novel complement inhibitors show promise in managing breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria, according ...

Improvement in IIM activity, as measured by the International Myositis Assessment and Clinical Studies Group (IMACS) definitions of improvement (DOI), may be more likely with abatacept treatment ...

Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton ...

Discover new safety insights on Syfovre for geographic atrophy treatment, as Roger A. Goldberg highlights promising long-term data at ASRS 2025.

Explore the growing U.S. Zilbrysq (Zilucoplan) market, projected to expand at a CAGR of 21.64% post-FDA approval for anti-AChR antibody-positive generalized myasthenia gravis (gMG). The subcutaneous ...

Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet. Click here to read an analysis of APLS ...

Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular ...

Key Points GAAP EPS loss was $(0.88) for Q2 2025 GAAP revenue was $0.2 million for Q2 2025 Research and development expenses increased by 45.3%, while general and administrative expenses rose by 48.3% ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...